Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cluster-randomized trial compares the Abbott ID NOW point-of-care test with the standard laboratory-based RT-PCR pathway for diagnosing influenza-like illness in residents of long-term care facilities. The aim is to see if rapid, on-site testing improves timely clinical decisions, infection control, and resource use. Eligible participants are residents aged 65+ with acute fever and respiratory symptoms, or high suspicion of influenza by the clinician. The study uses a real-world setting in Taichung, Taiwan, to evaluate diagnostic timing, antiviral initiation, and potential downstream health outcomes. Outcomes of interest include time to result, antiviral treatment timing, infection-control actions, and hospitalization rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Acute onset of illness with fever (tympanic temperature ≥38°C) persisting for at least 24 hours.
* Acute onset of illness accompanied by decreased oxygen saturation (e.g., SpO₂ decreased to 94% or deterioration in oxygenation), or influenza infection highly suspected by the treating physician.
* Residents aged 65 years or older with comorbidities (e.g., diabetes mellitus, dialysis, hypertension, heart disease, or use of immunosuppressive agents) who develop acute illness with fever (tympanic temperature ≥37.5°C) persisting for at least 24 hours.
* At least one respiratory symptom, such as cough, sore throat, or rhinorrhea, persisting for at least 24 hours.

Exclusion Criteria:

* A definite alternative diagnosis identified at the initial assessment that explains the influenza-like illness, such as bacterial pneumonia, non-respiratory infection, aspiration pneumonia following choking during feeding, definite urinary tract infection, or known exacerbation of heart failure without evidence of infection.
* Refusal by the resident or the resident's legally authorized representative to provide informed consent for data collection.
* Expected survival of less than 48 hours, as assessed by a physician.
* Participation in this study within the previous 14 days, to avoid duplicate enrollment for the same illness episode.
* Residence in a dedicated dementia care unit, because differences in disease characteristics, communication ability, and care practices may affect the internal validity of the study.

Where it's running

• China Medical University Hospital
  Taichung, Taiwan Recruiting

Study contacts

• Study coordinator: Chia-Hui Tan, Ph.D
• Email: elisetan@mail.cmu.edu.tw
• Phone: 886-4-2205-3366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Mucosal and Systemic Immunity and Protection Against Flu in 2- to 5-Year-Olds

  This observational study will see if blood and nasal immune responses in children aged 2–5 years can predict who gets influenza during the season.

  Recruiting National Institute for Communicable Diseases, South Africa · Jouberton, North West · NCT07861854

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions

  This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07645534

• Light-based immune boost to help prevent viral upper respiratory infections

  A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.

  Recruiting Mike O'Callaghan Military Hospital · Nellis Air Force Base, Nevada · NCT07610967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.